SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results
The approval by the US FDA comes after extensive safety testing and manufacturing improvements
NewCo’s pipeline includes five investigational medicines
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
The company expects meaningful revenue contribution from this long-term agreement
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Divestment is part of BASF’s strategic portfolio optimization
Subscribe To Our Newsletter & Stay Updated
